Neurogene
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Neurogene generated cash of -$51,422,000, which is more than the previous year. Cash used in financing activities reached the amount of $92,482,000 last year. Net change in cash is therefore $66,697,000.
Cash Flow
| 2015 | -20.26M | -47.53M | 92.94M |
|---|---|---|---|
| 2017 | -44.71M | 64.01M | 423K |
| 2019 | -15.39M | -688K | 82.23M |
| 2020 | -24.57M | -2.21M | 77.13M |
| 2021 | -46.4M | -18.36M | 51.06M |
| 2022 | -52.82M | -2.23M | 66.53M |
| 2023 | -51.42M | 25.63M | 92.48M |
NGNE Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 82.02M | 70.54M | 84.25M | 143.09M | 76.92M | 32.30M | 14.90M |
Operating activities | |||||||
Net income | -36.31M | -55.18M | -50.51M | -33.27M | -69.44M | -50.18M | -21.86M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 3.29M | 3.2M | 947K | 1.82M | 340K | 0 | 0 |
Stock-based compensation expense | 1.41M | 1.25M | 896K | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 1.41M | 1.25M | 896K | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 290K | 0 | 34K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 667K | -3.60M | 2.98M | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -51.42M | -52.82M | -46.4M | -24.57M | -15.39M | -44.71M | -20.26M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | -5.99M | -60.70M |
Investments In Property Plant And Equipment | -321K | -2.23M | -18.36M | -2.21M | -879K | -494K | -27K |
Acquisitions Net | 0 | 0 | 0 | 0 | 191K | 0 | 1K |
Cash generated by investing activities | 25.63M | -2.23M | -18.36M | -2.21M | -688K | 64.01M | -47.53M |
Financing activities | |||||||
Common Stock Issued | 92.34M | 66.53M | 783K | 77.18M | 82.24M | 438K | 92.94M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -29K | -1K | -51K | -49K | -9K | -15K | 0 |
Cash used in financing activities | 92.48M | 66.53M | 51.06M | 77.13M | 82.23M | 423K | 92.94M |
Net Change In Cash | 66.69M | 11.47M | -13.70M | 49.46M | 66.16M | 19.73M | 0 |
Cash at end of period | 148.71M | 82.02M | 70.54M | 192.55M | 143.09M | 52.03M | 39.52M |
| Data source |